142 related articles for article (PubMed ID: 639053)
1. Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents.
Kataoka T; Kobayashi H; Sakurai Y
Cancer Res; 1978 May; 38(5):1202-7. PubMed ID: 639053
[No Abstract] [Full Text] [Related]
2. Enhanced induction of immune resistance by concanavalin A-bound L1210 vaccine and an immunopotentiator prepared from Coriolus versicolor.
Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
Cancer Res; 1977 Dec; 37(12):4416-9. PubMed ID: 922733
[TBL] [Abstract][Full Text] [Related]
3. 6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine.
Kataoka T; Akahori Y; Sakurai Y
Cancer Res; 1984 Feb; 44(2):519-24. PubMed ID: 6537896
[TBL] [Abstract][Full Text] [Related]
4. Induction of resistance to L1210 leukemia in BALB/c X DBA/2Cr F1 mice, with L1210 cells treated with glutaraldehyde and concanavalin A.
Kataoka T; Oh-hashi F; Tsukagoshi S; Sakurai Y
Cancer Res; 1977 Apr; 37(4):964-8. PubMed ID: 403001
[TBL] [Abstract][Full Text] [Related]
5. Chemical and biological adjuvants capable of potentiating tumor cell vaccine.
Chirigos MA; Stylos WA; Schultz RM; Fullen JR
Cancer Res; 1978 Apr; 38(4):1085-91. PubMed ID: 416906
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432.
Kataoka T; Oh-hashi F; Sakurai Y
Cancer Res; 1979 Jul; 39(7 Pt 1):2807-10. PubMed ID: 445486
[TBL] [Abstract][Full Text] [Related]
7. Immunoprophylactic and immunotherapeutic response by concanavalin A-bound tumor vaccine enhanced by chemotherapeutic agents eliminating possible suppressors.
Kataoka T; Ogihara K; Sakurai Y
Cancer Res; 1980 Oct; 40(10):3839-45. PubMed ID: 6449286
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
Nicolin A; Canti G; Goldin A
Cancer Res; 1974 Nov; 34(11):3044-8. PubMed ID: 4424774
[No Abstract] [Full Text] [Related]
9. Chemoimmunotherapy of L1210 leukemia with adriamycin, cyclophosphamide, and OK-432, and their effects on the generation of antitumor immunity.
Ujiie T
Jpn J Cancer Res; 1987 Jul; 78(7):737-47. PubMed ID: 3114200
[TBL] [Abstract][Full Text] [Related]
10. In vivo potentiation of concanavalin A-bound L1210 vaccine by antimacrophage agents.
Kataoka T; Oh-hashi F; Sakurai Y; Gomi K
Cancer Res; 1980 Oct; 40(10):3832-8. PubMed ID: 6254642
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of L1210 murine leukemia vaccine in vivo by levamisole.
Kataoka T; Tsukagoshi S; Sakurai Y; Okabe M
Gan; 1979 Aug; 70(4):515-9. PubMed ID: 510850
[TBL] [Abstract][Full Text] [Related]
12. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy.
Mathé G; Kamel M; Dezfulian M; Halle-Pannenko O; Bourut C
Cancer Res; 1973 Sep; 33(9):1987-97. PubMed ID: 4146853
[No Abstract] [Full Text] [Related]
13. L1210 leukemia regression in non-immunosuppressed mice with therapeutic transfer of immune spleen cells--therapeutic adoptive transfer against L1210 leukemia.
Kawashima K; Nagura E; Nagase F; Kumazawa T; Nakashima I; Yamada K
Nihon Ketsueki Gakkai Zasshi; 1987 Sep; 50(6):1174-82. PubMed ID: 3687342
[No Abstract] [Full Text] [Related]
14. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275
[No Abstract] [Full Text] [Related]
15. Blastogenic potency of concanavalin-A-bound L1210 leukemic vaccine associated with its immunogenic activity.
Kataoka T; Oh-hashi F; Sakurai Y
Gan; 1979 Apr; 70(2):155-64. PubMed ID: 111995
[TBL] [Abstract][Full Text] [Related]
16. Preliminary characterization in mice of the effect of isoprinosine on the immune system.
Vecchi A; Sironi M; Spreafico F
Cancer Treat Rep; 1978 Nov; 62(11):1975-9. PubMed ID: 83191
[TBL] [Abstract][Full Text] [Related]
17. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
Nicolin A; Canti G; Marelli O; Veronese F; Goldin A
Cancer Res; 1981 Apr; 41(4):1358-62. PubMed ID: 7011535
[TBL] [Abstract][Full Text] [Related]
19. Post-surgical systematic active immunotherapy: rational and experimental basis.
Mathé G; Olsson L; Florentin I; Kiger N; Orbach-Arbouys S; Schulz JI
Recent Results Cancer Res; 1979; 67():132-50. PubMed ID: 377432
[No Abstract] [Full Text] [Related]
20. Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice.
Lasek W; Sora M; Wańkowicz A; Jakóbisiak M
Cancer Lett; 1995 Feb; 89(1):137-43. PubMed ID: 7882296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
